Difference between revisions of "Icotinib (Conmana)"
m |
Warner-admin (talk | contribs) m |
||
Line 23: | Line 23: | ||
[[Category:EGFR inhibitors]] | [[Category:EGFR inhibitors]] | ||
− | |||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:NMPA approved drugs]] | [[Category:NMPA approved drugs]] |
Revision as of 19:03, 8 May 2022
General information
Class/mechanism from the NCI Drug Dictionary: An orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Also known as
- Code name: BPI-2009H
- Brand name: Conmana